Alluvi, previously BI 4744, represents a significant breakthrough in obesity care. This dual agonist targeting both glucagon-like peptide-1 and GIP sites demonstrates remarkable effectiveness in clinical studies, https://alluvipeptides033239.ziblogs.com/profile